Literature DB >> 24118133

Septal perforator anatomy and variability of perfusion bed by myocardial contrast echocardiography: a study of hypertrophic cardiomyopathy patients undergoing alcohol septal ablation.

Eric L Wallace1, J Jenkins Thompson, Michael W Faulkner, John C Gurley, Mikel D Smith.   

Abstract

OBJECTIVE: To characterize the perfusion bed of the first septal perforator by myocardial contrast echocardiography (MCE) in patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation (ASA).
BACKGROUND: MCE is used to define the septal perforator anatomy prior to ASA. Occasionally, ASA cannot be performed due to unfavorable septal anatomy or perfusion outside the interventricular septum. Despite the standard use of MCE for septal mapping, there are no reports describing the territory of septal perforator perfusion.
METHODS: Forty-seven consecutive patients underwent ASA between 1/1/2004 and 12/30/2012. Blinded individuals retrospectively evaluated patients for septal perforator anatomic findings. Patients were divided into 2 groups based on presence or absence of extra-septal perfusion (ESP) as visualized by apical views after intracoronary contrast injection. The groups' procedural outcomes were compared, including infarct size, new conduction abnormalities, and major adverse events.
RESULTS: Over 25% demonstrated ESP, of which 83% predominantly involved the right ventricular (RV) moderator band. The first septal perforator (FSP) was statistically larger in ostial diameter (1.69 mm vs. 1.23 mm, P = 0.04) and numerically more likely dominant in patients with ESP (63.6% vs. 47.2%, P = 0.22). In those with ESP, the odds ratio comparing FSP diameter of 2.0 mm to the mean was 1.96 (95% CI: 1.01-3.80).
CONCLUSIONS: Downstream capillary perfusion may be discordant from epicardial territory and this study emphasizes the importance of MCE prior to ASA. Over 25% of our patients demonstrated ESP, most commonly involving the RV moderator band. The size of the FSP was the strongest predictor of ESP.
© 2013, Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24118133     DOI: 10.1111/joic.12068

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  4 in total

1.  Intracardiac echocardiography for percutaneous transluminal septal myocardial ablation in the treatment of hypertrophic obstructive cardiomyopathy.

Authors:  Takayuki Onishi; Yuko Onishi; Isshi Kobayashi; Keiko Tachibana; Shigeo Umezawa; Akihiro Niwa
Journal:  J Echocardiogr       Date:  2015-07-21

2.  Intra-cardiac echocardiography in alcohol septal ablation: a prospective comparative study against trans-thoracic echocardiography.

Authors:  Robert M Cooper; Adeel Shahzad; James Newton; Niels Vejlstrup; Anna Axelsson; Vishal Sharma; Oliver Ormerod; Rodney H Stables
Journal:  Echo Res Pract       Date:  2015-02-02

3.  Targeting Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy Candidates for Surgical Myectomy: Added Value of Three-Dimensional Intracoronary Myocardial Contrast Echocardiography.

Authors:  Giovanni La Canna; Iside Scarfò; Irina Arendar; Antonio Colombo; Lucia Torracca; Davide Margonato; Matteo Montorfano; Ottavio Alfieri
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

Review 4.  Role of endocardial septal ablation in the treatment of hypertrophic obstructive cardiomyopathy.

Authors:  Tolga Aksu; Tümer Erdem Güler; Kıvanç Yalın; Şükriye Ebru Gölcük; Kazım Serhan Özcan
Journal:  Anatol J Cardiol       Date:  2016-09       Impact factor: 1.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.